AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone

NCT00395967 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Enrollment terminated in 2005 to focus on Phase 3 study enrollment.

Conditions

Multiple Myeloma
Lymphoma, Non-Hodgkin's

Interventions

DRUG: G-CSF plus plerixafor

Sponsor

Genzyme, a Sanofi Company